Arie Goren Blog | Talkmarkets | Page 1
Global Analyst
Contributor's Links: Portfolio123

Arie Goren is a senior global analyst at Sigma Wealth Management/ ANDBANK GROUP. He has 37 years of experience in the world financial markets specialized mostly in the American stock markets and commodities. Arie Goren has been writing many investment articles in important financial websites and ... more

All Contributions

Latest Posts
1 to 16 of 40 Posts
1 2 3
E Superb Valuation, Micron Technology Stock Is Very Attractive
Micron's fundamentals are excellent, its valuation ratios indicate an undervalued stock, and it has high growth prospects. New applications like the IoT, AI, Big Data and Cloud will need an increasing amount of memory which will benefit the company.
E Finding Bargains Among S&P 500 Stocks
The recent declines at the U.S. stock market have created an excellent opportunity to find some big bargains among S&P 500 stocks with a good chance of a significant price appreciation when the market starts to rally.
E Is Now The Right Time To Consider Lam Research?
Lam Research will benefit from increasing future demand for memory chips. This is due to new applications such as the Internet of Things, Artificial Intelligence, Big Data and the Cloud. The company's fundamentals are excellent.
E A Dividend Portfolio That Can Outperform The Market By A Big Margin
A portfolio of twenty S&P 500 companies yielding more than 2% a year and having the highest research and development expense to revenue ratio is giving excellent results.
E Is Low P/E The Key To Pick Top Performers?
I tried to find out if there was a correlation between the top 25 S&P 500 performers in the last 52 weeks ending on May 11, to their price-earnings ratio a year ago on May 11, 2017. One year doesn't tell the tale.
E Small Cap Stocks: Gainers And Losers In 2017
Here are the best and the worst performers among Russell 2000 stocks in 2017, and 20 stocks that have a chance to perform well in 2018, which should be a better year for investors in small cap stocks.
E Large Cap Stocks: Gainers And Losers In 2017
Here are the best and the worst performers among Russell 1000 stocks in 2017, and 20 stocks that have a chance to perform well in 2018, which should be another good year for investors in large cap stocks.
E What To Expect From Apple's Earnings Report
The average target price of the top analysts is at $176.22, which indicates an upside of 12.3% from its October 13th price,
E Apple Supplier Broadcom Has Topped Estimates Again
Apple's supplier Broadcom delivered above-consensus results for its second fiscal quarter, with broad-based gains across multiple markets. Broadcom revenue and earnings could grow even more later with the launch of Apple's new iPhone.
E Why Ligand Pharmaceuticals Is A Good Long-Term Investment Opportunity
Ligand is a fast growing biotech company with a distinctive business model. Investors can participate in the high-promising biotech industry by investing in LGND stock with lower-risk than investing in a typical high-growth biotechnology company.
E New Technologies And Manufacturing Lead Will Drive Intel Stock Higher
Intel is well positioned to return to sustainable growth. The company continues to advance Moore’s Law which gives it a significant product and cost benefits. Intel has three year lead over the rest of the industry on 14-nanometer semiconductor.
E Cisco Systems Stock Is A Great Long-Term Investment
Cisco has compelling valuation and is paying a generous dividend yielding 3.39% after increasing its dividend by 12%. Cisco is continuing to focus on growth driven by its plan to shift toward software and subscription-based product & services model.
E T. Rowe Price Group Could Benefit From Snapchat IPO
According to market sources, the planned Snapchat IPO is oversubscribed, which could benefit TROW due to its large holding in Snapchat shares. The average target price of the top analysts is at $82, representing an upside of 14% from its last price.
E Gilead Sciences Is Now More Attractive After Showing Superior Results Of Its Newest HIV Drug
Gilead's stock is extremely undervalued, and it still has high growth prospects due to new revolutionary drugs in its pipeline and a possible big acquisition. The average target price of the top analysts is at $84.17, an upside of 24.6%.
E Best Russell 1000 Energy Stocks According To Buffett Principles: Consider Tesoro
Despite challenging market conditions characterized by lower crack spreads, Tesoro delivered better than expected fourth quarter results. Moreover, TSO sees attractive refining market environment in 2017, and high demand for gasoline by consumers.
E Corning Still Has Substantial Growth Drivers
Corning delivered strong fourth quarter results and it expects year over year growth in the first quarter of 2017.The company is committed to returning substantial capital to its shareholders by stock buybacks and increasing dividend.
1 to 16 of 40 Posts
1 2 3